• The leader in hyperspectral imaging for superficial tissue oximetry

  • A new generation of advanced portable imaging is coming

  • Building upon our proven technology to establish a new standard of care

Welcome to HyperMed

HyperMed Imaging, Inc. is the established leader in medical hyperspectral imaging for surface tissue oximetry. Our pioneering technology has been in service since 2006 and has been shown in published clinical research to effectively assess oxyhemoglobin, deoxyhemoglobin and oxyhemoglobin saturation in superficial tissue for a number of key healthcare applications.

HyperMed has developed a new product using the same breakthrough imaging technology as used in HyperMed’s OxyVu™-1 system. HyperMed’s new product, called HyperView™, is FDA 510(k) cleared. HyperView is designed to deliver the same diagnostic information in a smaller, more portable configuration.

The Company

Hypermed Comp Img2
Hypermed Comp Img3
Hypermed Comp Img1
Hypermed Comp Img4

What are the Biomarkers of Tissue Health?

Levels of oxyhemoglobin, deoxyhemoglobin and oxygen saturation are key biomarkers of interest to assess tissue health. Assessing oxygenation in superficial tissue helps clinicians understand the localized vascular system’s ability to support tissue viability.

The Need

The Need

There are many medical applications requiring a need to quickly and efficiently determine surface tissue oxygenation. Ischemic tissue leads to complications such as non-healing wounds and surgical intervention.

Read more

The Solution

The Solution

HyperMed’s technology utilizes a proprietary form of hyperspectral imaging that is a novel and patented solution for superficial tissue oximetry. HyperMed has 34 issued patents and over 40 pending worldwide.

Read more

HyperMed Imaging, Inc. is not offering for sale any medical device at this time.
HyperMed’s new tissue oximetry device called HyperView™ is FDA 510(k) cleared.
HyperMed, HyperView, OxyVu™-1 and the company logo are trademarks of HyperMed Imaging, Inc.